Undisclosed SNAP-CAR NK therapy / Coeptis - LARVOL DELTA

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 (PRNewswire) - "Coeptis Therapeutics Holdings...announced today that the Company has been selected for an oral presentation of the abstract titled Developing A First-In-Class Universal Allogeneic Snap-Car NK Cell Therapy at the International Society for Cell & Gene Therapy 2024, being held May 28th to June 1st in Vancouver, Canada....'Our presentation represents a significant and meaningful path forward in advancing our mission to develop a proprietary, allogeneic cell generation platform aimed at universalizing the treatment of many debilitating diseases.'" "

Preclinical • Oncology

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (PRNewswire) - "Coeptis Therapeutics Holdings, Inc...is pleased to announce that the Company's abstract for development of SNAP-CAR NK cells will be featured as a poster presentation at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held virtually and in-person in Baltimore, MD on May 7-11, 2024....Dr. Carrie Stoltzman, Director of Cell Biology at Deverra Therapeutics will be presenting data on behalf of Coeptis regarding the development of the SNAP-CAR NK platform, designed to target multiple antigens and potentially address a wide range of cancers."

Clinical • Immunology • Oncology

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (PRNewswire) - "Coeptis Therapeutics Holdings, Inc...today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T Cells, a 'universal' CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, and a recent amendment to the agreement for SNAP-CAR NK, an allogeneic natural killer (NK) cell therapy platform....'We remain committed to developing these remarkable technologies as treatments for various indications across oncology where there is immense unmet need.'"

Licensing / partnership • Hematological Malignancies • Immunology • Oncology • Solid Tumor